NFE2L2 and cancer: Because several genes mutations such as TP53, TERT, CDKN2A, PBRM1, SETD2, EGFR, ATM, KEAP1 and STK11 were found to affect the prognosis of cancer patients[28, 49–51], we selected 1816 patients from two immunotherapy cancer cohorts including MSK cohort and MSK1661 cohort, sufficient genes mutation information and clinical characteristics to conduct multivariate Cox regression model with confounding factors adjusted, revealing no significant association of Nrf2-activating MU with shorter OS (HR: 0.97, 95% CI 0.68 − 1.39; Fig. 5E).